Within laboratory environments, GHK-Cu is frequently investigated in experimental models examining peptide interaction, signalling mechanisms and biochemical pathway modulation
IV administration is used in some clinical settings to support liver function in patients with specific conditions - though this is not a reason to self-prescribe
Twelve-week Mediterranean diet intervention increases citrus bioflavonoid levels and reduces inflammation in people with type 2 diabetes mellitus
Ketamine: a tale of two enantiomers[J/OL]
This boost to the immune system may contribute to better overall health and resilience
Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]